Bank of America Securities analyst Travis Steed has reiterated their bullish stance on BSX stock, giving a Buy rating yesterday.
Travis Steed has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong performance and potential for growth. The company reported an impressive 18% organic revenue growth in the first quarter, positioning it among the fastest-growing medtech companies. Notably, their operating margins exceeded expectations, reaching 28.9% compared to the anticipated 27.1%, resulting in a significant increase in operating profit. This margin improvement was driven by substantial growth in their electrophysiology and Watchman product lines.
Additionally, Boston Scientific’s strategic measures to counteract the anticipated $200 million tariff impact in 2025 demonstrate resilience and adaptability. The company successfully offset this challenge through revenue growth and cost-cutting initiatives, such as transitioning global meetings to a virtual format. Despite some challenges in their Medsurg segment, the company is expanding its portfolio to remain competitive and is investing in areas like neuromodulation to sustain momentum. These factors collectively support the Buy rating, reflecting confidence in Boston Scientific’s ability to navigate market challenges and capitalize on growth opportunities.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $124.00 price target.
Based on the recent corporate insider activity of 131 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.